ABSTRACT
[This corrects the article DOI: 10.4102/ajlm.v10i1.1296.].
ABSTRACT
BACKGROUND: Interaction between multiple myeloma (MM) cells and proximal monocytes is expected during plasma cell proliferation. However, the role of monocyte subsets in the disease progression is unknown. OBJECTIVE: This study evaluated circulating monocyte populations in MM patients and their correlation with disease severity. METHODS: Peripheral monocytes from 20 patients with MM attending Assiut University Hospital in Assiut, Egypt, between October 2018 and August 2019 were processed using a flow cytometry procedure and stratified using the intensity of expression of CD14 and CD16 into classical (CD16-CD14++), intermediate (CD16+CD14++), and non-classical (CD16++CD14+) subsets. The data were compared with data from 20 healthy control participants with comparable age and sex. RESULTS: In patients with MM, the percentage of classical monocytes was significantly lower (mean ± standard error: 77.24 ± 0.66 vs 83.75 ± 0.5), while those of non-classical (12.44 ± 0.5 vs 8.9 ± 0.34) and intermediate (10.3 ± 0.24 vs 7.4 ± 0.29) monocytes were significantly higher when compared with those of controls (all p < 0.0001). Proportions of non-classical and intermediate monocytes correlated positively with serum levels of plasma cells, M-protein, calcium, creatinine and lactate dehydrogenase, and correlated negatively with the serum albumin level. Proportions of classical monocytes correlated positively with albumin level and negatively correlated with serum levels of M-protein, plasma cells, calcium, creatinine, and lactate dehydrogenase. CONCLUSION: Circulating monocyte subpopulations are skewed towards non-classical and intermediate monocytes in MM patients, and the intensity of this skewness increases with disease severity.
ABSTRACT
This study was performed to determine the role of autophagy-related 16-like 1 (ATG16L1, rs2241880) and IL10 (rs1800872) polymorphisms in the susceptibility to and early prediction of breast cancer in Egyptians. The study included 50 breast cancer patients and 50 apparently healthy controls. The PCR-RFLP technique was used to detect ATG16L1 (rs2241880) and IL10 (rs1800872) genotypes. IL10 level was determined in serum by ELISA. The mean age of the patients was 54.2 years. Among the patients, 80% had no family history for breast cancer, 70% were postmenopausal, and 72% exhibited grade II tumors. Metastasis was detected in 18% of the patients, and 6% of the cases exhibited triple-negative receptor (TNR) status. In the ATG16LI (rs2241880) gene, the GG genotype frequency was significantly higher in patients than in controls (14% in patients versus 2% in controls, P =0.02), and no metastasis was observed in patients with the AA genotype (P=0.03). In the IL10 (rs1800872) gene, the A allele was observed in 30% of patients and 23% of controls, but the difference was insignificant (P=0.26). Also, the prevalence of the AA genotype was 8% in patients and 4% in controls (P=0.54). Serum IL10 levels were higher in patients than in controls (P < 0.001). Within the patient group, individuals with the IL10 (rs1800872) AA genotype showed significantly higher serum IL10 levels than those with the CC and CA+CC genotypes (P =0.03 and 0.04, respectively). In conclusion, in Egyptian breast cancer patients, the GG genotype of ATG16LI (rs2241880) may be associated with increased disease risk, and the AA genotype could be protective against metastasis.
